PDF(1043 KB)
PDF(1043 KB)
PDF(1043 KB)
血清miR-17-92基因簇对视网膜母细胞瘤诊断价值的研究
Value of serum miR-17-92 cluster in diagnosis of retinoblastoma
目的 分析血清miR-17-92基因簇对视网膜母细胞瘤（RB）的诊断价值。方法 采用实时定量PCR法检测20例RB患儿、20名健康对照者的血清miR-17-92基因簇表达水平，分析其在不同分期RB患儿的表达差异及综合治疗前后的变化，并采用ROC曲线判断其对RB的诊断价值。结果 RB患儿血清中miR-17-92基因簇成员miR-17-3P、miR-17-5P、miR-18a和miR-20a的相对表达量均高于健康对照组，以miR-18a升高更为显著，差异均有统计学意义（P < 0.05）；两组miR-19a、miR-19b-1和miR-92a-1相对表达量的差异无统计学意义（P > 0.05）。miR-17-5P、miR-17-3P、miR-18a和miR-20a表达量在早中期和晚期RB患儿之间的差异均无统计学意义（P > 0.05），但综合治疗后表达量显著降低（P < 0.05）。miR-17-3P、miR-17-5P、miR-18a和miR-20a对RB诊断价值的曲线下面积（AUC）分别为0.770、0.755、0.828和0.665，以miR-18a的AUC最大，并具有较好的灵敏度（90%）和特异度（65%）。结论 miR-17-92基因簇的miR-17-3P、miR-17-5P、miR-18a和miR-20a在RB患儿血清中高表达，miR-18a有可能作为RB诊断的新指标。
Objective To investigate the value of serum miR-17-92 cluster in the diagnosis of retinoblastoma (RB). Methods Serum samples were collected from 20 children with RB and 20 healthy controls. Quantitative real-time PCR was used to measure the expression of miR-17-92 cluster. The expression of miR-17-92 cluster was compared between children with different stages of RB and the changes in the expression of miR-17-92 cluster after multimodality therapy were analyzed. The receiver operating characteristic (ROC) curve was used to investigate the value of serum miR-17-92 cluster in the diagnosis of RB. Results Compared with the healthy controls, the children with RB had signifcantly higher relative expression of miR-17-3P, miR-17-5P, miR-18a, and miR-20a in serum (P < 0.05), and miR-18a showed the greatest increase. There were no signifcant differences in the relative expression of miR-19a, miR-19b-1, and miR-92a-1 between children with RB and healthy controls (P > 0.05). There were no signifcant differences in the expression of miR-17-5P, miR-17-3P, miR-18a, and miR-20a between the children with early-to-moderate stage of RB and those with advanced stage of RB (P > 0.05), but there were signifcant reductions after multimodality therapy (P < 0.05). In the diagnosis of RB, the areas under the ROC curve (AUCs) for serum miR-17-3P, miR-17-5P, miR-18a, and miR-20a were 0.770, 0.755, 0.828, and 0.665 respectively, and miR-18a had the largest AUC, with a sensitivity of 90% and a specifcity of 65%. Conclusions miR-17-3P, miR-17-5P, miR-18a, and miR-20a are highly expressed in the serum of children with RB, and miR-18a may be used as a new marker for the diagnosis of RB.
Retinoblastoma / microRNA / Diagnosis / Child
[1] Ortiz MV, Dunkel IJ. Retinoblastoma[J]. J Child Neurol, 2016, 31(2):227-236.
[2] Chang CY, Chiou TJ, Hwang B, et al. Retinoblastoma in Taiwan:survival rate and prognostic factors[J]. Jpn J Ophthalmol, 2006, 50(3):242-249.
[3] Attar M, Arefian E, Nabiuni M, et al. MicroRNA 17-92 expressed by a transposone-based vector changes expression level of cell-cycle-related genes[J]. Cell Biol Int, 2012, 36(11):1005-1012.
[4] Lillington DM, Kingston JE, Coen PG, et al. Comparative genomic hybridization of 49 primary retinoblastoma tumors identifes chromosomal regions associated with histopathology, progression, and patient outcome[J]. Genes Chromosomes Cancer, 2003, 36(2):121-128.
[5] Kandalam MM, Beta M, Maheswari UK, et al. Oncogenic microRNA 17-92 cluster is regulated by epithelial cell adhesion molecule and could be a potential therapeutic target in retinoblastoma[J]. Mol Vis, 2012, 18:2279-2287.
[6] Dimaras H, Kimani K, Gallic BL, et al. Retinoblastoma[J]. Lancet, 2012, 379(9824):1436-1446.
[7] 路璐, 唐松, 郭慧, 等. 全身化学药物治疗对晚期视网膜母细胞瘤患儿肿瘤浸润和眼外转移及特定疾病生存率的影响[J]. 中华眼底病杂志, 2016, 32(4):404-407.
[8] 刘智屏, 陈俐丽, 李博, 等. 鞘内化疗防治视网膜母细胞瘤颅内转移疗效观察[J]. 海南医学, 2016, 27(19):3211-3213.
[9] 国芳, 姚玮艳, 戴欣, 等. 血清miRNA作为胃癌早期诊断标记物的初步研究[J]. 胃肠病学, 2014, 19(4):198-202.
[10] 王建仓, 赵敬聪, 赵军阳, 等. 早期视网膜母细胞瘤激光光凝治疗效果[J]. 中华眼视光学与视觉科学杂志, 2014, 16(6):376-378.
[11] MacCarthy A, Birch JM, Draper GJ, et al. Retinoblastoma:treatment and survival in Great Britain 1963 t02002[J]. Br J Ophthalmol, 2009, 93:38-39.
[12] 胡慧敏, 王一卓, 黄东生, 等. 视网膜母细胞瘤患儿化疗前后血清及脑脊液实验室指标的变化[J]. 中华实用儿科临床杂志, 2015, 30(15):1157-1160.
[13] Andreas E, Hoelker M, Neuhoff C, et al. MicroRNA 17-92 cluster regulates proliferation and differentiation of bovine granulosa cells by targeting PTEN and BMPR2 genes[J]. Cell Tissue Res, 2016, 366(1):219-230.
[14] Dellago H, Bobbili MR, Grillari J. MicroRNA-17-5p:At the crossroads of cancer and aging-A mini-review[J]. Gerontology, 2017, 63(1):20-28.
[15] Brockway S, Zeleznik-Le NJ. WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia[J]. Cancer Genet, 2015, 208(5):279-287.
[16] 于宇, 张淑兰. miR-17-92基因簇研究进展[J]. 国际妇产科学杂志, 2014, 41(2):124-127.
[17] Conkrite K, Sundby M, Mukai S, et al. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma[J]. Genes Dev, 2011, 25(16):1734-1745.
[18] Nittner D, Lambertz I, Clermont F, et al. Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation[J]. Nat Cell Biol, 2012, 14(9):958-965.
[19] Yang Y, Mei Q. miRNA signature identification of retinoblastoma and the correlations between differentially expressed miRNAs during retinoblastoma progression[J]. Mol Vis, 2015, 21:1307-1317.
[20] Fadakar P, Akbari A, Ghassemi F, et al. Evaluation of SD-208, a TGF-β-RI kinase inhibitor, as an anticancer agent in retinoblastoma[J]. Acta Med Iran, 2016, 54(6):352-358.
[21] Jo DH, Kim JH, Cho CS, et al. STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters[J]. Oncotarget, 2014, 5(22):11513-11525.
深圳市卫生计生系统科研项目（编号：20151007）。
